Glenview State Bank Trust DEPT. boosted its position in Celgene Co. (NASDAQ:CELG) by 1.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 20,400 shares of the biopharmaceutical company’s stock after acquiring an additional 250 shares during the quarter. Glenview State Bank Trust DEPT.’s holdings in Celgene were worth $1,308,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also recently bought and sold shares of the stock. Legacy Financial Advisors Inc. lifted its holdings in Celgene by 61.8% during the 4th quarter. Legacy Financial Advisors Inc. now owns 825 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 315 shares during the last quarter. Csenge Advisory Group acquired a new stake in shares of Celgene during the 3rd quarter worth approximately $90,000. Global Trust Asset Management LLC grew its position in shares of Celgene by 217.9% during the 4th quarter. Global Trust Asset Management LLC now owns 1,459 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 1,000 shares during the period. Valeo Financial Advisors LLC grew its position in shares of Celgene by 92.1% during the 4th quarter. Valeo Financial Advisors LLC now owns 1,959 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 939 shares during the period. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Celgene during the 3rd quarter worth approximately $132,000. Institutional investors and hedge funds own 72.71% of the company’s stock.
Several brokerages have recently commented on CELG. Zacks Investment Research upgraded shares of Celgene from a “sell” rating to a “hold” rating in a research report on Monday, December 31st. Cantor Fitzgerald reissued a “buy” rating and issued a $100.00 price objective on shares of Celgene in a research report on Thursday, January 31st. Jefferies Financial Group downgraded shares of Celgene from a “buy” rating to a “hold” rating and set a $95.00 target price on the stock. in a report on Friday, February 1st. Canaccord Genuity downgraded shares of Celgene from a “buy” rating to a “hold” rating in a report on Thursday, January 3rd. Finally, BidaskClub downgraded shares of Celgene from a “hold” rating to a “sell” rating in a report on Wednesday, October 24th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Celgene currently has an average rating of “Buy” and a consensus target price of $109.29.
CELG stock opened at $88.14 on Wednesday. The stock has a market capitalization of $61.39 billion, a PE ratio of 11.58, a P/E/G ratio of 0.41 and a beta of 1.72. The company has a debt-to-equity ratio of 4.06, a current ratio of 2.13 and a quick ratio of 1.99. Celgene Co. has a 12 month low of $58.59 and a 12 month high of $97.43.
Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 EPS for the quarter, topping analysts’ consensus estimates of $2.32 by $0.07. The firm had revenue of $4.04 billion during the quarter, compared to analysts’ expectations of $3.98 billion. Celgene had a net margin of 26.48% and a return on equity of 125.35%. During the same quarter in the prior year, the business earned $2.00 earnings per share. As a group, analysts anticipate that Celgene Co. will post 9.87 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Celgene Co. (CELG) Shares Bought by Glenview State Bank Trust DEPT.” was first reported by Equities Focus and is owned by of Equities Focus. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.equitiesfocus.com/2019/02/06/celgene-co-celg-shares-bought-by-glenview-state-bank-trust-dept.html.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: How to read a candlestick chart
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.